<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1864">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04435795</url>
  </required_header>
  <id_info>
    <org_study_id>2021-6696</org_study_id>
    <nct_id>NCT04435795</nct_id>
  </id_info>
  <brief_title>Inhaled Ciclesonide for Outpatients With COVID19</brief_title>
  <acronym>CONTAIN</acronym>
  <official_title>Ciclesonide Clinical Trial for COVID-19 Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CONTAIN (CiclesOnide cliNical TriAl covId-19 treatmeNt) is a randomized control study of&#xD;
      ciclesonide vs placebo for mild covid-19 disease. The need for potential therapy for COVID-19&#xD;
      patients is urgent. Ciclesonide has shown encouraging in vitro results, is easy to be used&#xD;
      and is readily available. It has a low rate of side effects and few interactions with other&#xD;
      drugs. It is unusual to use an inhaled steroid drug for COVID-19 but there has been new data&#xD;
      suggesting steroids may have an antiviral effect in addition to an anti-inflammatory effect.&#xD;
      Investigators propose to use inhaled and nasal ciclesonide to stop viral replication in the&#xD;
      nose and airways. Investigators hope this will accelerate recovery from COVID-19 illness in&#xD;
      individuals who are not admitted to hospital at time of diagnosis of COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">March 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with no symptoms of cough, fever or dyspnea</measure>
    <time_frame>day 7</time_frame>
    <description>Proportion of participants with no symptoms of cough, fever or dyspnea at day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in dyspnea</measure>
    <time_frame>day7</time_frame>
    <description>&quot;Dyspnea improvement&quot; is defined as a 15%, or greater, decline in dyspnea intensity using the Promis Dyspnea characteristics scale administered at day 7 in patients who declare dyspnea at day 1. In patients who declare chest tightness/chest congestion/dry or wet cough at study entry we will define a change as a 2-point improvement using a visual analog scale from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for SARS-CoV-2</measure>
    <time_frame>day 14</time_frame>
    <description>Hospitalization for SARS-CoV-2 related illness at day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Use</measure>
    <time_frame>day 14</time_frame>
    <description>Incidence of new oxygen use during the trial (defined as oxygen use not present at randomization) at day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Use</measure>
    <time_frame>day 14</time_frame>
    <description>Duration of new oxygen use during the trial (defined as oxygen use not present at randomization) at day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>day 14 and 29</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status</measure>
    <time_frame>day 7 and 14</time_frame>
    <description>Ordinal Scale for evaluating subject Clinical Status from o to 10 ( 0 uninfected and 10 death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>day 7, 10 and 14</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System (PROMIS)Anxiety 7a scale from 1 to 5 (1never had symptoms and 5 always had symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Disturbance</measure>
    <time_frame>day 7, 10 and 14</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep disturbance 4a scale from 1 to 5 (1being very good and 5 being very poor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog scale</measure>
    <time_frame>day 7, 10 and 14</time_frame>
    <description>Visual Analog scale from 0-10 indicating improvement in respiratory symptoms such as chest tightness/chest congestion/dry or wet cough at day 7,10 and14 ( 0 being completely resolved and 10 being the worst they've been)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">454</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>Ciclesonide inhaled and nasal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal ciclesonide BID 50mcg BID to each nostril and inhaled cilcesonide 600mcg BID x 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline intranasal</intervention_name>
    <description>Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID</description>
    <arm_group_label>Ciclesonide inhaled and nasal</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Symptomatic adult patients positive by PCR for COVID-19 within 5 days of enrollment.&#xD;
        Provision of Informed Consent&#xD;
&#xD;
        At Day 0, patients should be at home&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Already on inhaled corticosteroid medication&#xD;
&#xD;
          -  Currently using systemic steroids (oral or intravenous or intramuscular such as&#xD;
             Prednisone) or use of steroids 7 days prior to enrolment&#xD;
&#xD;
          -  Severely ill patients at enrollment (i.e., admitted to ICU at admission)&#xD;
&#xD;
          -  Unable to self-administer the inhaler&#xD;
&#xD;
          -  Anticipated transfer to another hospital within 72 hours which is not a study site&#xD;
&#xD;
          -  Known or suspected pregnancy&#xD;
&#xD;
          -  Known allergy to study medication or its components (non-medicinal ingredients;&#xD;
             including lactose allergy (type I))&#xD;
&#xD;
          -  Patients with untreated fungal, bacterial or tubercular infections of the respiratory&#xD;
             tract&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicole Ezer</last_name>
    <phone>(514)-934-1934</phone>
    <phone_ext>76192</phone_ext>
    <email>nicole.ezer@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia Naderi</last_name>
    <email>nafiseh.naderi@mail.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3K 2M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>nicole ezer</last_name>
      <phone>5148675447</phone>
      <email>nicole.ezer@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>James Martin, MD DSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Lee, MD MPH FIDSA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily McDonald, MD MSc, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Bartlett</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Benedetti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Smith, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Belga Sara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Nicole Ezer, MD, FRCPC, MPH</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

